Jan Medical has secured $7.5 million Series C funding to support further development and clinical trials of its non-invasive brain diagnostic tool for abnormal neurological conditions, such as concussion and stroke. Also, some of the money — provided by Brainlab — will be used to obtain the FDA clearance and CE Mark registration for the company’s flagship product called BrainPulse. And as part of the deal, Ken Bruener, Vice President of Marketing and Business Development at Brainlab, will join Jan Medical’s Board of Directors.

BrainPulse captures a novel, physiological signal that utilizes the cardiac output to measure vasculature and brain tissue conditions.“This Series C funding further validates the potential of the BrainPulse device, as we accelerate our regulatory clearances and prepare for market launch,” Paul Lovoi, PhD, President and CEO of Jan Medical, said in a statement. “We are fortunate to collaborate with such an exciting, passionate team from a leading neuroscience company.”

BrainPulse captures a novel, physiological signal that utilizes the cardiac output to measure vasculature and brain tissue conditions. The data captured by the device has been shown to detect and longitudinally observe sports-related concussion in a clinical trial at Stanford University, as reported in the Clinical Journal of Sport Medicine.

In another early trial published by Neurocritical Care, BrainPulse detected vasospasm with clinically meaningful accuracy at the University of California San Francisco (UCSF). Additional clinical trials in concussion detection and vasospasm are ongoing.